0001209191-23-059814.txt : 20231227
0001209191-23-059814.hdr.sgml : 20231227
20231227172640
ACCESSION NUMBER: 0001209191-23-059814
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231222
FILED AS OF DATE: 20231227
DATE AS OF CHANGE: 20231227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hohl Benjamin
CENTRAL INDEX KEY: 0001882764
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39247
FILM NUMBER: 231518879
MAIL ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Enliven Therapeutics, Inc.
CENTRAL INDEX KEY: 0001672619
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: 720-647-8519
MAIL ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
FORMER COMPANY:
FORMER CONFORMED NAME: IMARA Inc.
DATE OF NAME CHANGE: 20160419
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-22
0
0001672619
Enliven Therapeutics, Inc.
ELVN
0001882764
Hohl Benjamin
C/O ENLIVEN THERAPEUTICS, INC.
6200 LOOKOUT ROAD
BOULDER
CO
80301
0
1
0
0
Chief Financial Officer
1
Common Stock
2023-12-22
4
M
0
1030
2.48
A
1030
D
Common Stock
2023-12-22
4
S
0
1030
15.0728
D
0
D
Common Stock
2023-12-26
4
M
0
100
2.48
A
100
D
Common Stock
2023-12-26
4
S
0
100
15.00
D
0
D
Employee Stock Option (right to buy)
2.48
2023-12-22
4
M
0
1030
0.00
D
2031-08-02
Common Stock
1030
261090
D
Employee Stock Option (right to buy)
2.48
2023-12-26
4
M
0
100
0.00
D
2031-08-02
Common Stock
100
260990
D
The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
This transaction was executed in multiple trades at prices ranging from $15.00 to $15.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.
/s/ Benjamin Hohl
2023-12-27